GO:0015862 uridine transmembrane transport: Nucleoside Salvage Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015862 (uridine transmembrane transport) describes the directed movement of uridine, a uracil riboside, across a lipid bilayer via a transporter or pore.
• Uridine transport is essential for nucleotide salvage, RNA synthesis, and cellular energy metabolism, particularly in tissues with high nucleotide demand such as the intestine and brain.
• Nucleoside transporters, including members of the equilibrative nucleoside transporter (ENT) and concentrative nucleoside transporter (CNT) families, mediate uridine uptake.
• Dietary uridine supplementation stimulates intestinal development and upregulates nucleotide transport in weaned piglets, demonstrating its physiological importance.
• Genetic polymorphisms in nucleoside transporters can influence the pharmacokinetics and response to nucleoside analog drugs such as mycophenolic acid.
• CRISPR-based knockout, knock-in, and overexpression models are powerful tools to dissect the causal roles of uridine transporters in health and disease [3,7].
Description
Uridine transmembrane transport (GO:0015862) is the biological process by which uridine, a pyrimidine nucleoside composed of uracil linked to ribose, is moved across a lipid bilayer. This process is fundamental for cellular nucleotide homeostasis, as uridine serves as a precursor for RNA synthesis and can be salvaged to generate uridine triphosphate (UTP) and cytidine triphosphate (CTP). Unlike de novo synthesis, salvage pathways rely on the efficient uptake of exogenous nucleosides, making transmembrane transport a critical regulatory node. Researchers study uridine transport to understand how cells acquire nucleotides under normal and stressed conditions, and how this process contributes to diseases ranging from cancer to neurological disorders [7,8]. The identification of specific nucleoside transporter genes in protozoan parasites such as Leishmania has provided early insights into the molecular machinery of uridine uptake. In mammalian systems, equilibrative and concentrative nucleoside transporters facilitate uridine movement across plasma membranes, and their expression is tightly regulated in response to metabolic demands. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a comprehensive overview of GO:0015862, its genetic players, regulatory mechanisms, and experimental approaches for investigation.
uridine transmembrane transport At A Glance
| GO ID | GO:0015862 |
|---|---|
| GO term | uridine transmembrane transport |
| Ontology | biological_process |
| Synonym | none |
| Major function | Mediates the movement of uridine across cellular membranes, supporting nucleotide salvage and RNA synthesis [3,7] |
| Cellular location | Plasma membrane, mitochondrial membrane, and other organelle membranes |
| Key transporters | Equilibrative nucleoside transporters (ENTs), concentrative nucleoside transporters (CNTs), and parasite-specific nucleoside transporters |
| Physiological relevance | Essential for intestinal development, nucleotide homeostasis, and drug pharmacokinetics [7,8] |
| Research methods | CRISPR knockout, transport assays, RNA profiling, and pharmacokinetic studies [3,7,8] |
What Is GO:0015862?
According to the Gene Ontology, GO:0015862 (uridine transmembrane transport) is defined as the directed movement of uridine, uracil riboside, across a lipid bilayer, by means of some agent such as a transporter or pore. This process encompasses the translocation of uridine from one side of a membrane to the other, either down its concentration gradient (facilitated diffusion) or against it (active transport), and is mediated by specialized membrane proteins.
Why Is uridine transmembrane transport Important in Cell Biology?
Uridine transmembrane transport is a cornerstone of nucleotide metabolism, enabling cells to utilize exogenous uridine for RNA synthesis, energy transfer, and glycosylation reactions. Its importance extends to pharmacology, as many nucleoside analog drugs rely on the same transporters for cellular entry, and genetic variations in these transporters can alter drug efficacy and toxicity. In rapidly proliferating tissues, such as the intestinal epithelium, efficient uridine uptake is critical for growth and repair, as demonstrated by dietary nucleotide supplementation studies in weaned piglets. Moreover, understanding uridine transport in pathogens like Leishmania can reveal vulnerabilities for antiparasitic drug development.
• Supports nucleotide salvage pathways, reducing the metabolic cost of de novo synthesis.
• Facilitates intestinal development and repair in young animals, as shown by uridine monophosphate supplementation.
• Influences the pharmacokinetics of nucleoside analog drugs, including mycophenolic acid.
• Plays a role in purinergic signaling and extracellular nucleotide metabolism.
• Is a potential target for antiparasitic therapies, as nucleoside transporters are essential in Leishmania.
• Contributes to RNA homeostasis and cellular stress responses.
• May be involved in neuroprotective mechanisms through uridine availability.
• Genetic polymorphisms in transporters can affect drug response and disease susceptibility.
• Provides a model for studying membrane transport mechanisms and transporter structure-function relationships.
• Links dietary nucleotide intake to systemic metabolic regulation.
What Happens During uridine transmembrane transport?
Substrate Recognition and Binding
In simple terms: The transporter protein recognizes uridine and grabs it.
The first step in uridine transmembrane transport involves the specific binding of uridine to a membrane-embedded transporter protein. Equilibrative nucleoside transporters (ENTs) and concentrative nucleoside transporters (CNTs) exhibit distinct substrate affinities and selectivities. In Leishmania, nucleoside transporter genes were cloned by rescue of a transport-deficient mutant, demonstrating that specific protein factors are required for uridine uptake. This binding step is highly selective, ensuring that only uridine and structurally related nucleosides are recognized, which is critical for maintaining nucleotide pool balance.
Conformational Change and Translocation
In simple terms: The transporter changes shape to move uridine across the membrane.
Upon uridine binding, the transporter undergoes a series of conformational changes that translocate the substrate from the extracellular side to the intracellular side of the lipid bilayer. This process can be driven by concentration gradients (facilitated diffusion) or by ion gradients (active transport). The molecular details of these conformational transitions have been inferred from studies of related transporters and from functional assays in model membranes. The energy for concentrative transport is often provided by sodium or proton gradients, whereas equilibrative transporters simply facilitate downhill movement.
Release and Intracellular Availability
In simple terms: Uridine is released inside the cell for use.
After translocation, uridine is released into the cytoplasm, where it becomes available for salvage pathways. It can be phosphorylated by uridine kinase to form uridine monophosphate (UMP), which is a precursor for UTP and CTP. In weaned piglets, dietary uridine supplementation increased the expression of genes involved in nucleotide transport and promoted intestinal development, indicating that intracellular uridine availability directly impacts tissue growth. The released uridine can also be catabolized or used in glycosylation reactions.
Regulation of Transporter Activity
In simple terms: The cell controls how much uridine gets in.
The activity of uridine transporters is regulated at multiple levels, including gene expression, post-translational modifications, and membrane trafficking. For example, in TBEV-infected neurons and astrocytes, integrative RNA profiling revealed changes in the expression of genes related to nucleoside transport, suggesting that viral infection can modulate transport capacity. Additionally, genetic polymorphisms in nucleoside transporters can alter their function and influence drug pharmacokinetics, as seen with mycophenolic acid. This regulation ensures that uridine uptake matches cellular demands for nucleotides and energy.
Integration with Nucleotide Metabolism
In simple terms: Uridine transport connects to the cell's nucleotide factory.
Uridine transmembrane transport is tightly integrated with intracellular nucleotide metabolism. Once inside, uridine enters the salvage pathway and contributes to the pools of UTP and CTP, which are essential for RNA synthesis and protein glycosylation. In purinergic signaling, extracellular nucleotides and nucleosides, including uridine, can activate receptors and influence various physiological processes. The interplay between transport and metabolism ensures that cells can adapt to fluctuations in nutrient availability and metabolic stress.
Key Genes Involved in GO:0015862 uridine transmembrane transport
The following genes and proteins are experimentally implicated in uridine transmembrane transport or related nucleoside transport processes, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC29A1 (ENT1) | Equilibrative nucleoside transporter 1; mediates facilitated diffusion of uridine and other nucleosides | Target for studying nucleoside analog drug uptake and resistance |
| SLC29A2 (ENT2) | Equilibrative nucleoside transporter 2; transports uridine and other nucleosides | Involved in nucleoside homeostasis in various tissues |
| SLC28A1 (CNT1) | Concentrative nucleoside transporter 1; sodium-dependent uridine transport | Potential target for drug delivery and cancer therapy |
| SLC28A2 (CNT2) | Concentrative nucleoside transporter 2; sodium-dependent uridine transport | Studied for its role in intestinal and renal nucleoside absorption |
| SLC28A3 (CNT3) | Concentrative nucleoside transporter 3; broad selectivity including uridine | Associated with drug response variability |
| Leishmania NT1 | Nucleoside transporter in Leishmania; essential for uridine uptake | Model for antiparasitic drug development |
| Leishmania NT2 | Nucleoside transporter in Leishmania; transports uridine and other nucleosides | Cloned by rescue of transport-deficient mutant |
| UCKL1 | Uridine-cytidine kinase 1; phosphorylates uridine to UMP | Links transport to nucleotide salvage |
| UCK2 | Uridine-cytidine kinase 2; phosphorylates uridine and cytidine | Involved in pyrimidine salvage |
| CMPK1 | Cytidine monophosphate kinase; converts UMP to UDP | Downstream of uridine salvage |
| NME1 | Nucleoside diphosphate kinase; maintains nucleotide pools | Indirectly related to uridine utilization |
| ENT3 (SLC29A3) | Intracellular equilibrative nucleoside transporter | May transport uridine across organelle membranes |
| P2RX7 | Purinergic receptor involved in nucleotide signaling | Linked to extracellular nucleotide metabolism |
| P2RY2 | Purinergic receptor for UTP and ATP | May sense extracellular uridine nucleotides |
| NT5E (CD73) | Ecto-5'-nucleotidase; generates extracellular uridine | Produces uridine from UMP |
| ENT4 (SLC29A4) | Equilibrative nucleoside transporter 4; pH-dependent | Potential role in uridine transport |
| CNT2 (SLC28A2) | Concentrative nucleoside transporter 2; sodium-dependent | Intestinal uridine uptake |
How Is uridine transmembrane transport Regulated?
Uridine transmembrane transport is regulated at transcriptional, post-transcriptional, and post-translational levels. In response to metabolic stress or viral infection, cells can alter the expression of nucleoside transporter genes, as observed in TBEV-infected neural cells where RNA profiling revealed changes in transport-related transcripts. Dietary nucleotide supplementation in weaned piglets upregulated genes involved in nucleotide transport, indicating nutritional regulation. Additionally, genetic polymorphisms in transporter genes can affect their function and influence drug pharmacokinetics, as reviewed for mycophenolic acid. Hormonal and inflammatory signals may also modulate transporter activity, although specific pathways remain to be fully elucidated.
uridine transmembrane transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC29A1 (ENT1) | Drug response variability in immunosuppression | Knockout cell lines for mycophenolic acid uptake assays |
| Leishmania NT1 | Leishmaniasis | Leishmania transport-deficient mutants for drug screening |
| SLC28A2 (CNT2) | Intestinal development and nutrition | Weaned piglet model with dietary uridine supplementation |
| SLC29A3 (ENT3) | Histiocytosis and lysosomal storage disorders | Knockout mice or patient-derived cells |
| P2RX7 | Neuroinflammation and purinergic signaling | P2RX7 knockout models for uridine nucleotide signaling |
Uridine Transport in Infectious Diseases
Pathogens such as Leishmania rely on nucleoside transporters to scavenge uridine from the host, and the cloning of Leishmania nucleoside transporter genes by rescue of a transport-deficient mutant highlights their essentiality for parasite survival. In viral infections like TBEV, integrative RNA profiling of infected neurons and astrocytes revealed altered expression of genes related to nucleoside transport, suggesting that viruses may manipulate host transport machinery to support their replication. These findings position uridine transporters as potential targets for antimicrobial and antiviral therapies.
Uridine Transport and Drug Pharmacokinetics
Nucleoside transporters mediate the cellular uptake of many therapeutic nucleoside analogs, including mycophenolic acid. Genetic polymorphisms in genes such as SLC29A1 and SLC28A3 can alter drug pharmacokinetics and treatment response, as shown in a scoping review of mycophenolic acid. Understanding uridine transport mechanisms is therefore critical for predicting inter-individual variability in drug efficacy and toxicity, and for designing personalized dosing strategies.
Uridine Transport in Intestinal Development and Nutrition
Dietary supplementation with uridine monophosphate or uridine stimulates intestinal development and promotes nucleotide transport in weaned piglets. This indicates that uridine transport is not only a housekeeping function but also a responsive process that can be enhanced by nutritional interventions. The study demonstrated increased expression of genes involved in nucleotide transport, linking dietary uridine to improved gut health and growth performance.
Uridine Transport in Neurological and Purinergic Signaling
Uridine and other nucleosides participate in purinergic signaling, which regulates diverse neurological processes. Extracellular uridine can be generated by ectonucleotidases and may influence neuronal function through receptor-mediated pathways. In TBEV-infected neurons, altered nucleoside transport gene expression suggests a role in neuropathogenesis. Further research is needed to clarify how uridine transport contributes to brain physiology and disease.
From uridine transmembrane transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of SLC29A1 reduce uridine uptake? | CRISPR knockout in HeLa or HEK293 cells |
| Can a point mutation in SLC28A2 alter substrate specificity? | CRISPR point mutation knock-in in intestinal epithelial cells |
| Does overexpression of Leishmania NT1 increase uridine transport? | Overexpression in transport-deficient Leishmania |
| How does tagged SLC29A1 localize in neurons? | Knock-in of fluorescent tag in iPSC-derived neurons |
| What is the effect of uridine supplementation on transporter expression? | Weaned piglet model with dietary uridine |
| Can CRISPR screening identify novel uridine transporters? | Genome-wide CRISPR library screening in nucleoside auxotrophs |
How to Study the uridine transmembrane transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled uridine uptake | Transport activity | Characterization of transporter kinetics |
| RNA-seq | Gene expression changes | Identifying transporters regulated by infection or diet [1,7] |
| CRISPR knockout | Loss-of-function effects | Determining essentiality of transporter genes |
| CRISPR activation | Gain-of-function effects | Identifying genes that enhance uridine uptake |
| Pharmacokinetic profiling | Drug levels in blood/tissues | Assessing impact of polymorphisms on drug response |
| Fluorescent tagging | Subcellular localization | Visualizing transporter trafficking |
| Inhibitor studies | Transport mechanism | Distinguishing ENT vs CNT activity |
| Dietary intervention | Physiological outcomes | Testing uridine supplementation effects |
Transport Assays
Radiolabeled or fluorescent uridine uptake assays are the gold standard for measuring transport activity. Cells expressing candidate transporters are incubated with labeled uridine, and intracellular accumulation is quantified. This method was used to clone Leishmania nucleoside transporter genes by rescuing a transport-deficient mutant. Inhibitor studies can distinguish between equilibrative and concentrative transport mechanisms.
RNA Profiling and Transcriptomics
RNA sequencing and integrative RNA profiling can reveal changes in the expression of nucleoside transporter genes under various conditions. For example, TBEV-infected neurons and astrocytes showed altered expression of transport-related genes, providing insights into host-pathogen interactions. In weaned piglets, dietary uridine supplementation modulated the expression of genes involved in nucleotide transport, as assessed by transcriptomic analysis.
Pharmacokinetic and Pharmacogenomic Studies
Pharmacokinetic studies measure drug absorption, distribution, and elimination, often in the context of genetic polymorphisms in transporter genes. A scoping review of mycophenolic acid highlighted how variants in SLC29A1 and SLC28A3 influence drug exposure and response. These approaches are essential for personalized medicine and for predicting drug-drug interactions at the transporter level.
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout or activation screens can identify genes that regulate uridine transport. By using nucleoside auxotrophic cell lines or selecting for resistance to nucleoside analogs, researchers can uncover novel transporters and regulatory factors. Such screens have been instrumental in dissecting nucleotide salvage pathways and can be adapted to study uridine-specific transport.
How CRISPR Can Be Used to Study GO:0015862 uridine transmembrane transport
Knockout
CRISPR knockout of nucleoside transporter genes such as SLC29A1 or SLC28A2 can abolish uridine uptake, providing direct evidence of their function. This approach has been used to validate transporter genes in Leishmania by rescuing transport-deficient mutants. In mammalian cells, knockout models help determine the contribution of specific transporters to overall uridine flux and drug sensitivity.
Point Mutation
CRISPR point mutation knock-in can introduce specific amino acid substitutions to study transporter structure-function relationships. For example, mutating residues in the substrate-binding pocket of SLC28A2 can reveal determinants of uridine selectivity. Such models are valuable for understanding how genetic polymorphisms affect transport activity and drug response.
Knock-in
Knock-in of fluorescent or epitope tags into endogenous transporter loci allows real-time visualization of protein localization and trafficking. Tagged SLC29A1 knock-in cells can be used to track uridine transporter dynamics in response to stimuli. This approach preserves endogenous regulatory elements, providing physiologically relevant expression levels.
Overexpression
Overexpression of uridine transporters, such as Leishmania NT1 or human SLC29A1, can enhance transport capacity and is useful for gain-of-function studies. Overexpression models are also employed to study drug uptake and resistance, as increased transporter levels can sensitize cells to nucleoside analogs.
How EDITGENE Supports uridine transmembrane transport Research
Researchers studying uridine transmembrane transport-related genes often need to determine whether a candidate gene is causally involved in uridine uptake, how mutations affect transporter function, and whether modulating expression alters cellular phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for uridine transmembrane transport research.
Frequently Asked Questions About uridine transmembrane transport
What is uridine transmembrane transport?
Uridine transmembrane transport (GO:0015862) is the directed movement of uridine, a uracil riboside, across a lipid bilayer by means of a transporter or pore.
What genes are involved in uridine transmembrane transport?
Key genes include SLC29A1 (ENT1), SLC29A2 (ENT2), SLC28A1 (CNT1), SLC28A2 (CNT2), SLC28A3 (CNT3), and Leishmania nucleoside transporter genes NT1 and NT2 [3,8].
How is uridine transported into cells?
Uridine is transported by equilibrative nucleoside transporters (ENTs) via facilitated diffusion or by concentrative nucleoside transporters (CNTs) via sodium-dependent active transport.
Why is uridine transport important for intestinal development?
Dietary uridine supplementation stimulates intestinal development and promotes nucleotide transport in weaned piglets, indicating a role in gut growth and repair.
Can uridine transport affect drug efficacy?
Yes, nucleoside transporters mediate the uptake of drugs like mycophenolic acid, and genetic polymorphisms can alter pharmacokinetics and treatment response.
What diseases are linked to uridine transport?
Leishmaniasis, viral infections, and drug response variability are associated with uridine transport mechanisms [1,3,8].
How can I study uridine transmembrane transport in the lab?
Common methods include radiolabeled uridine uptake assays, RNA-seq, CRISPR knockout, and pharmacokinetic profiling [3,7,8].
What is the role of Leishmania nucleoside transporters?
Leishmania NT1 and NT2 are essential for uridine uptake and were cloned by rescuing transport-deficient mutants, making them potential drug targets.
Are there genetic disorders caused by mutations in uridine transporters?
Mutations in SLC29A3 (ENT3) are associated with histiocytosis and lysosomal storage disorders, though direct links to uridine transport require further study.
How does CRISPR help in studying uridine transport?
CRISPR knockout, knock-in, and overexpression models allow precise manipulation of transporter genes to determine their function and regulation [3,7,8].
Conclusion
Uridine transmembrane transport (GO:0015862) is a vital biological process that ensures cellular availability of uridine for nucleotide salvage, RNA synthesis, and energy metabolism. Its relevance spans infectious diseases, drug pharmacokinetics, and intestinal development, as evidenced by studies in Leishmania, weaned piglets, and pharmacogenomic reviews [3,7,8]. Advances in CRISPR-based gene editing and integrative RNA profiling continue to unravel the molecular players and regulatory mechanisms underlying this process [1,3]. Understanding uridine transport not only illuminates fundamental cell biology but also opens avenues for therapeutic intervention in infectious diseases and personalized medicine.
References
- 1. Selinger M et al.. 2022. Integrative RNA profiling of TBEV-infected neurons and astrocytes reveals potential pathogenic effectors.. Comput Struct Biotechnol J 20:2759-2777 PMID: 35685361
- 3. Vasudevan G et al.. 1998. Cloning of Leishmania nucleoside transporter genes by rescue of a transport-deficient mutant.. Proc Natl Acad Sci U S A 95(17):9873-8 PMID: 9707568
- 4. van Dam V et al.. 2007. Transmembrane transport of peptidoglycan precursors across model and bacterial membranes.. Mol Microbiol 64(4):1105-14 PMID: 17501931
- 5. Lazarowski ER et al.. 2009. [Purinergic signals].. Medicina (B Aires) 69(2):267-76 PMID: 19435702
- 7. Xie CY et al.. 2019. Dietary supplement with nucleotides in the form of uridine monophosphate or uridine stimulate intestinal development and promote nucleotide transport in weaned piglets.. J Sci Food Agric 99(13):6108-6113 PMID: 31177538
- 8. Yow HY et al.. 2024. Influence of genetic polymorphisms on pharmacokinetics and treatment response of mycophenolic acid: a scoping review.. Pharmacogenomics 25(5-6):259-288 PMID: 38884938
